Literature DB >> 18438661

Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases.

John Koutsikos, Anastasia Leondi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18438661     DOI： 10.1007/s00259-008-0759-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  6 in total

1.  [Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis].

Authors:  Jiu-gen Liang; Ning-yi Jiang; Jian-qiang DU; Xian-ping Lu; Xing-guang Liu; Shao-xiong Chen
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2005-03

Review 2.  186Re-HEDP for metastatic bone pain in breast cancer patients.

Authors:  Marnix G E H Lam; John M H de Klerk; Peter P van Rijk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-29       Impact factor: 9.236

Review 3.  The management of painful bone metastases with an emphasis on radionuclide therapy.

Authors:  Darren J Hillegonds; Stephen Franklin; David K Shelton; Srinivasan Vijayakumar; Vani Vijayakumar
Journal:  J Natl Med Assoc       Date:  2007-07       Impact factor: 1.798

Review 4.  153Sm-EDTMP for bone pain palliation in skeletal metastases.

Authors:  Carlo L Maini; Serenella Bergomi; Luisa Romano; Rosa Sciuto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-04       Impact factor: 9.236

5.  A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer.

Authors:  Rong Fu Wang; Chun Li Zhang; Shou Li Zhu; Mei Zhu
Journal:  Med Princ Pract       Date:  2003 Apr-Jun       Impact factor: 1.927

6.  Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.

Authors:  Marnix G E H Lam; Amel Dahmane; Wil H M Stevens; Peter P van Rijk; John M H de Klerk; Bernard A Zonnenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-22       Impact factor: 9.236
  6 in total
  1 in total

1.  Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone disease.

Authors:  Nigora Rasulova; Vladimir Lyubshin; Dauranbek Arybzhanov; Sh Sagdullaev; Valery Krylov; Marat Khodjibekov
Journal:  World J Nucl Med       Date:  2013-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.